<DOC>
	<DOC>NCT03039621</DOC>
	<brief_summary>The purpose of this study is to obtain additional data on efficacy and safety of Ergoferon in the treatment of acute respiratory viral infections in children aged from 6 months to 6 years.</brief_summary>
	<brief_title>Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>1. Patients of both sexes aged from 6 months to 6 years old . 2. Diagnosis of acute respiratory viral infection based on physician examination: oral temperature of at least 38.0°C at examination + total symptom severity score ≥5. 3. The first 24 hours from the beginning of manifestations of acute respiratory viral infection . 4. Patients presenting during a seasonal morbidity raise of acute respiratory viral infection. 5. Availability of a patient information sheet (Informed Consent form) signed by the patient's parents/adopters to confirm the child's participation in the clinical trial signed by one parent/adopter of patient. 1. Suspected pneumonia or bacterial infection (e.g. meningitis, sepsis, otitis media, urinary tract infection, etc.) requiring antibacterial therapy starting from Day 1 of the illness onset. 2. Suspected initial manifestations of diseases that have symptoms similar to ARVI (other infectious diseases, influenzalike syndrome at the onset of Autoimmune Disorders of Connective Tissue, oncohematology and other pathology). 3. Clinical symptoms of severe influenza infection/ARVI requiring hospitalization. 4. Medical history or prior diagnosis of primary and secondary immunodeficient disease; oncology disease. 5. Exacerbation or decompensation of a chronic disease (diabetes mellitus, infantile cerebral palsy, mucoviscidosis/cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, сongenital malformations of the respiratory system and ETN, etc.) that would affect the patient's ability to participate in the clinical trial. 6. Malabsorption syndrome, including congenital or acquired lactose intolerance/lactase deficiency or any other disaccharidase deficiency and galactosemia. 7. Allergy/ intolerance to any of the components of medications used in the treatment. 8. Course intake of medicines listed in the section "Prohibited concomitant treatment" for 2 weeks prior to the enrollment in the trial. 9. Subjects whose parents/adopters, from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the intake regimen of the investigated medicines. 10. Participation in other clinical trials within 3 months prior to the enrollment in this study. 11. Patient's parents/adopters are related to the research staff of the clinical investigative site who are directly involved in the trial or are the immediate family member of the researcher. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted. 12. The patient's parent/adopter works for OOO "NPF "MATERIA MEDICA HOLDING" (i.e., is the company's employee, temporary contract worker or appointed official responsible for carrying out the research) or the immediate relative.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>